A new meta-analysis examined preconception antibiotics and the impact on fertility, pregnancy, miscarriage, and birth defects.

The most rigorously designed trial (to date) of intraovarian PRP demonstrated no improvements in # of mature oocytes obtained or # of live births versus no injections.

A new study examines the associations between COVID-19 infection with pregnancy and miscarriage rates, looking at the first ten weeks after fresh embryo transfer.

A study compared fertility and sexual markers in obese men with low testosterone and erectile dysfunction who took liraglutide, uFSH + HCG, or testosterone. These men separated into three groups based on their plans for parenthood; results showed impressive improvements on the GLP-1 agonist liraglutide.

A recent study compared GnRH antagonists in egg donor ovarian stimulation cycles. The first drug is a newer agent, elagolix (Orilissa), that is taken as a tablet at night. The older drug is an injectable agent called ganirelix (Fyremadel). How did elagolix stack up with eggs retrieved and embryos formed vs. ganirelix? Were there adverse events, like ovarian hyperstimulation or early LH surge? Results and what they mean for upcoming egg donor cycles are explored in this episode.

A new trial tested a new way to give FSH to improve ovarian function in obese women without PCOS who are struggling to conceive.

This study adds low-dose dexamethasone to letrozole in women with PCOS who failed to ovulate with letrozole alone. This study looked at ovulation, pregnancy, and live birth rates and took place at the Mayo Clinic from 2019 to 2022.

Women report their use of herbs and supplements to a fertility clinic that assesses for herb-drug interactions.

This is the first randomized controlled multi-arm trial comparing how three hCG trigger doses impact endogenous progesterone levels in IVF- fresh embryo transfer cycles.

This is the first meta-analysis published in seven years to look at associations between caffeine or coffee consumption and pregnancy loss. More details at www.yourfertilitypharmacist.com

This is the first randomized, placebo-controlled trial of the weight-loss drug liraglutide, brand names Victoza and Saxenda, in non-diabetic women with PCOS and obesity who had interest in conceiving.